Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. It offers two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. The company also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; obstetrics, gynecology, urology, internal medicine, and pediatrics medical services; ambulatory surgery center facilities services; and ancillary medical services. Further, it provides pre-implantation genetic screening testing, management consultancy, postpartum and rehabilitation care, maternal-child nursing, and other hospital- derived services. Additionally, the company is involved in property investment, and real estate development and operation activities; sale of medicines, consumables, and equipment; research and development of IVF related projects, including scientific research and related commercialization; and operates restaurant. Jinxin Fertility Group Limited was founded in 1951 and is headquartered in Chengdu, China.